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ABSTRACT
Diabetic retinopathy (DR) is a common
microvascular complication of diabetes mellitus
(DM) and is considered as the leading cause of
visual impairment in working-aged adults
worldwide. Dyslipidemia has been associated
with DR, but not with progression to the pro-
liferative form of DR, although the exact role in
the pathogenesis of DR and diabetic macular
edema (DME) remains controversial. As a result,
a reasonable question arising is whether control
of dyslipidemia may alter the course of DR.
Statins do not appear to have an impact on DR
progression. On the other hand, fenofibrate has
been found to significantly reduce the rate of
progression of DR in patients with pre-existing
mild DR, although it has no impact on patient’s
vision nor on the prevention of DR develop-
ment in patients with type 2 DM without DR.
An interesting point that needs further evalua-
tion is why patients without DR or those with
severe DR appear to have no benefit from
fenofibrate treatment.
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Diabetic retinopathy (DR) is a common
microvascular complication of diabetes mellitus
(DM) and is considered as the leading cause of
visual impairment in working-aged adults
worldwide. So far studies have found that
duration of diabetes, degree of hyperglycemia,
and hypertension are related to the progression
of DR [1]. Dyslipidemia has been also associated
with DR, but not with progression to the pro-
liferative form of DR. In fact, serum lipids have
been reported to be a risk factor for DR and
diabetic macular edema (DME), suggesting that
permeability changes in the retinal microvas-
culature result in extravascular accumulation of
lipoprotein deposits, although the exact role in
the pathogenesis of DR and DME remains con-
troversial. Moreover, a recent meta-analysis
demonstrated that total cholesterol (TC),
triglycerides (TGs), and low-density lipoprotein
(LDL) cholesterol were significantly higher in
persons with DME compared to those with DM
without DME [2]. Therefore, a reasonable ques-
tion arising is whether control of dyslipidemia
may alter the course of DR.
Das et al. in their meta-analysis found that
there was not a significant improvement for
lipid-lowering therapy compared with placebo
with respect to the progression of hard exudates
or severity of DME, although some of the
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studies included in the meta-analysis suggested
some benefit [2]. In addition, statins, which
reduce LDL and are widely used for the treat-
ment of dyslipidemia, do not appear to have an
impact on DR progression [3]. On the other
hand, fenofibrate has been found to be benefi-
cial in reducing the progression of DR in
patients with pre-existing retinopathy, inde-
pendent of its effect on dyslipidemia control
[4–6]. Specifically, fenofibrate is a peroxisome
proliferator activated receptor alpha (PPARa)
agonist, which reduces TGs and LDL and
increases high-density lipoprotein (HDL)
cholesterol. Its mechanism of action is postu-
lated to involve lipid metabolism, endothelial
function, anti-apoptosis, anti-inflammation,
and anti-oxidation, while its beneficial effect on
DR progression has been evaluated in two large
randomized clinical trials [4–6].
The Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) study was a multi-
center randomized trial, which evaluated the
effect of fenofibrate 200 mg/day in about 9795
adult patients with type 2 DM [4]. The results of
this study showed that the rate of first laser
treatment for DR was significantly reduced in
patients at the fenofibrate group compared to
controls over an average of 5 years (3.4% vs.
4.9%, respectively, HR 0.69). In addition, there
was a relative reduction in the need for laser
treatment of 36% with fenofibrate treatment in
thosewith anymaculopathy and of 38% in those
with proliferative DR [4, 5]. Of note, the effect of
fenofibratewas evident 8 months after treatment
with progressively greater benefits over time.
Apart from the analysis regarding the entire
cohort, a substudy in 1012 patients, whose DR
was graded on the basis of Early Treatment
Diabetic Retinopathy Study (ETDRS) criteria,
was conducted to investigate the progression of
DR [5]. In this study, there was no difference in
the proportion of patients with a two-step pro-
gression in DR between patients in the fenofi-
brate and control group (9.6% vs. 12.3%,
respectively, p = 0.19). However, in patients
with pre-existing DR, significantly fewer
patients in the fenofibrate group showed a
two-step progression compared to those in the
placebo group (3.1% vs. 14.6%, p = 0.009). On
the contrary, the number of patients without
pre-existing DR who had a two-step progression
of DR was similar in the two groups (11.4% vs.
11.7%, p = 0.87), while the incidence of any new
DRwas not different between the two groups [5].
It is also worthy to note that the FIELD study
found that the benefit in the progression of DR
or the reduction in the need for laser treatment
was unrelated to serum lipid levels, suggesting a
complex association between serum dyslipi-
demia and DR/DME [4, 5].
The other large randomized controlled trial
evaluating the effect of the management of
systemic factors (hyperglycemia, hypertension,
hyperlipidemia) on the progression of DR was
the Action to Control Cardiac Risk in Diabetes
(ACCORD) eye study, comprising 2856 subjects
with type 2 DM [6, 7]. After 4 years, the pro-
portion of patients who presented with pro-
gression of DR of three or more steps on the
ETDRS severity scale or required laser photoco-
agulation/vitrectomy was significantly less in
patients receiving fenofibrate 160 mg/day plus
statin than in those receiving statin alone (6.5%
vs. 10.2%, respectively, p = 0.006), while there
was no statistically significant difference in the
rates of moderate visual loss or macular edema
between the two groups [6, 7]. Furthermore, no
significant difference in progression of DR was
observed for those without any DR and for
those with moderate or severe non-proliferative
disease [6]. However, this beneficial effect of
fenofibrate in reducing DR progression no
longer persisted after discontinuation of treat-
ment 4 years post ACCORD study closeout, with
11.8% of patients in the fenofibrate group and
10.2% of patients in the control group pre-
senting with DR progression (p = 0.60) [7].
In any case, it should be noted that although
the control of dyslipidemia is important, it has
to be taken into account that there may be an
interplay between various risk factors and dys-
lipidemia in patients with DR [8]. Blood pres-
sure is one of the most significant factors that
may interact with dyslipidemia in patients with
DM, but the impact of its control on DR pro-
gression remains controversial. Esmann et al.
showed that hard exudates in DR were corre-
lated with the duration of DM, the blood pres-
sure, and the serum cholesterol levels,
suggesting that hard exudates seem to be a
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characteristic sign in the slow and insidious
development of DR, in which dyslipidemia and
blood pressure may interact [9]. However,
according to a recent meta-analysis, reduction
of blood pressure could not prevent or slow DR,
although treatment to reduce the blood pres-
sure of people with DM is warranted for other
health reasons [9, 10].
Taken as a whole, in both FIELD and
ACCORD eye studies fenofibrate has been found
to significantly reduce the rate of progression of
DR in patients with pre-existing mild DR,
although it has no impact on patient’s vision
nor on the prevention of DR development in
patients with type 2 DM without DR. An inter-
esting point that needs further evaluation is
why patients without DR or those with severe
DR appear to have no benefit from fenofibrate
treatment. Additionally, both trials did not use
optical coherence tomography (OCT) to assess
DME and none had DR as a primary endpoint.
Therefore, it would be of great interest to ana-
lyze the effect of fenofibrate in controlling DME
using OCT, as well as to investigate its impact
on the treatment of DME with anti-vascular
endothelial growth factors.
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